Ontology highlight
ABSTRACT: Background
In the earliest days of COVID-19 pandemic, the collection of dried blood spots (DBS) enabled public health laboratories to undertake population-scale seroprevalence studies to estimate rates of SARS-CoV-2 exposure. With SARS-CoV-2 seropositivity levels now estimated to exceed 94% in the United States, attention has turned to using DBS to assess functional (neutralizing) antibodies within cohorts of interest.Methods
Contrived DBS eluates from convalescent, fully vaccinated and pre-COVID-19 serum samples were evaluated in SARS-CoV-2 plaque reduction neutralization titer (PRNT) assays, a SARS-CoV-2 specific 8-plex microsphere immunoassay, a cell-based pseudovirus assay, and two different spike-ACE2 inhibition assays, an in-house Luminex-based RBD-ACE2 inhibition assay and a commercial real-time PCR-based inhibition assay (NAB-Sure™).Results
DBS eluates from convalescent individuals were compatible with the spike-ACE2 inhibition assays, but not cell-based pseudovirus assays or PRNT. However, the insensitivity of cell-based pseudovirus assays was overcome with DBS eluates from vaccinated individuals with high SARS-CoV-2 antibody titers.Conclusion
SARS-CoV-2 neutralizing titers can be derived with confidence from DBS eluates, thereby opening the door to the use of these biospecimens for the analysis of vulnerable populations and normally hard to reach communities.
SUBMITTER: Berman K
PROVIDER: S-EPMC10983952 | biostudies-literature | 2024 Apr
REPOSITORIES: biostudies-literature
Berman Katherine K Van Slyke Greta G Novak Hayley H Rock Jean M JM Bievenue Rachel R Damjanovic Amanda K AK DeRosa Kate L KL Mirabile Gianna G Girardin Roxie C RC Dupuis Alan P AP McDonough Kathleen A KA Parker Monica M MM Styer Linda M LM Mantis Nicholas J NJ
bioRxiv : the preprint server for biology 20240402
<h4>Background</h4>In the earliest days of COVID-19 pandemic, the collection of dried blood spots (DBS) enabled public health laboratories to undertake population-scale seroprevalence studies to estimate rates of SARS-CoV-2 exposure. With SARS-CoV-2 seropositivity levels now estimated to exceed 94% in the United States, attention has turned to using DBS to assess functional (neutralizing) antibodies within cohorts of interest.<h4>Methods</h4>Contrived DBS eluates from convalescent, fully vaccina ...[more]